Cardiovascular risk, hypertension, and NSAIDs

被引：33

作者：

White W.B. ^{[1
]}

机构：

[1] Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06030-3940

来源：

Current Rheumatology Reports | 2007年 / 9卷 / 1期

关键词：

Celecoxib; Naproxen; Angiotensin Converting Enzyme Inhibitor; Rofecoxib; Parecoxib;

D O I：

10.1007/s11926-007-0020-3

中图分类号：

学科分类号：

摘要：

During the past 2 years, a great deal of evaluation has been conducted on the cardiovascular (CV) effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors. This review focuses on the effects of the NSAIDs and COX-2 inhibitors on blood pressure and CV events. Clinical trial databases for NSAIDs and COX-2 inhibitors have shown varying levels of destabilization of blood pressure control in treated hypertensive patients as well as variable incident rates of the development of arrhythmias, congestive heart failure, myocardial infarction, and stroke. Nonselective and COX-2 selective NSAIDs can be used carefully in arthritis patients with hypertension and stable CV disorders (excluding congestive heart failure and moderate to severe kidney dysfunction) when the individual clinical benefit of anti-inflammatory therapy outweighs the CV and gastrointestinal risk. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：36 / 43

页数：7

共 48 条

[1]

Silverstein F.E., Faich G., Goldstein J.L., Et al., Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial, JAMA, 284, pp. 1247-1255, (2000)

[2]

Bombardier C., Laine L., Reicin A., Et al., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N Engl J Med, 343, pp. 1520-1528, (2000)

[3]

Mukherjee D., Nissen S.E., Topol E.J., Risk of cardiovascular events associated with selective COX-2 inhibitors, JAMA, 286, pp. 954-959, (2001)

[4]

Konstam M.A., Weir M.R., Reicin A., Et al., Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib, Circulation, 104, pp. 2280-2288, (2001)

[5]

Bresalier R.S., Sandler R.S., Quan H., Et al., Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial, N Engl J Med, 352, pp. 1092-1102, (2005)

[6]

Nussmeier N.A., Whelton A.A., Brown M.T., Et al., Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery, N Engl J Med, 352, pp. 1081-1091, (2005)

[7]

Gilroy D.W., Colville-Nash P.R., Willis D., Et al., Inducible cyclooygenase may have anti-inflammatory properties, Nat Med, 5, pp. 698-701, (1999)

[8]

Kiefer W., Dannhardt G., Novel insights and therapeutic applications in the field of inhibitors of COX-2, Curr Med Chem, 11, pp. 3147-3161, (2004)

[9]

Fosslien E., Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia, Crit Rev Clin Lab Sci, 37, pp. 431-502, (2000)

[10]

Hao C.M., Breyer M.D., Hypertension and cyclooxygenase inhibitors. Target: The renal medulla, Hypertension, 44, pp. 396-397, (2004)

← 1 2 3 4 5 →